Dr. Federica Amati Sets 4 Rules for GLP-1 Users as 1 in 10 Americans Have Tried Them
Updated
Updated · zoe.com · Jun 18
Dr. Federica Amati Sets 4 Rules for GLP-1 Users as 1 in 10 Americans Have Tried Them
3 articles · Updated · zoe.com · Jun 18
Summary
Amati says GLP-1 users need four safeguards—protein, hydration, nutrient-dense foods and resistance training—to protect muscle, bones and brain health while appetite is suppressed.
GLP-1 drugs cut food intake by 30%–40%, she says, so poor diet quality on lower intake can trigger nutrient deficiencies, dehydration, constipation and lean-mass loss even as weight falls.
Lean mass can account for 20%–40% of weight lost after the first months, making gradual dose increases, structured meals and strength work critical; she says diet also helps manage the nausea and constipation that drive many users to quit.
Amati says stopping abruptly often brings hunger back and weight regain within 6–12 months, while tapering off and shifting to higher-fiber, higher-volume foods can improve the odds of maintaining fat loss.
With over 90% of users accessing the drugs without full support, she argues GLP-1s can improve metabolic health but do not fix a poor diet on their own.
With new drugs to prevent muscle loss, are we entering an era of 'designer' weight loss without lifestyle change?
Weight loss drugs silence 'food noise,' but what hidden health crisis are they creating in the process?
If stopping these drugs leads to rapid fat regain, is this 'revolution' trapping millions in a cycle of dependency?
GLP-1 Medications in 2026: Usage Surges to 1 in 8 U.S. Adults, Transforming Obesity Care and Public Perception
Overview
As of June 2026, GLP-1 receptor agonists like Ozempic, Wegovy, and Mounjaro have expanded from diabetes treatments to popular options for weight management and other health benefits. These medications are usually prescribed for ongoing use, since their positive effects on blood sugar and weight loss tend to fade if treatment stops. The effectiveness of GLP-1 therapies varies: most patients lose 10% to 20% of their body weight over six to twelve months and keep it off while on the medication. This shift marks a major change in how chronic conditions like obesity are managed.